Targeting ST6Gal-I shows promise in reducing Alzheimer’s disease pathology

'I pray we can find a cure': Arabella at Athens hosts 12-hour fishing fundraiser for Alzheimer's

From sun up to sun down, anglers gathered at the Arabella of Athens to cast their lines to raise funds for the Alzheimer's Coalition of Henderson County.

Alzheimer's disease research offers hope for finding therapeutic target that stops progression

In searching for a possible therapeutic target to stop the progress of this disease, an international scientific team, led by researchers at the Department of Cell Biology, Genetics and Physiology of the UMA and also members of the Baglietto lab and the NeuroAD research group, has identified different factors involved in the propagation processes.

Targeting ST6Gal-I shows promise in reducing Alzheimer’s disease pathology

A recent study published in Engineering has provided novel insights into the involvement of α2,6-sialylation in Alzheimer's disease (AD), revealing that the ablation of α2,6-sialyltransferase-I (ST6Gal-I), an enzyme responsible for α2,6-sialylation, can downregulate BACE1 expression and suppress the production of amyloid-β42 (Aβ42) plaques, which are hallmarks of AD.